Thomas A. McKnight, M.D.
Cognitive Clinical Trials Research
8901 E. Pima Center Parkway, Suite 115
Scottsdale, AZ 85258

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicalTrials@alliancesites.com

AFFILIATIONS:

Prairie Fields Family Medicine
350 W. 23rd Street A
Fremont, NE 68025

Heritage Ridge/CCT
1502 Fort Crook Road S
Bellevue, NE 68005

The Heritage at Sterling Ridge/CCT
1111 Sterling Ridge Drive
Omaha, NE 68144

Heritage Pointe/CCT
16811 Burdette Street
Omaha, NE 68116

Legacy Oaks
17241 Oak Dr, Suite 101
Omaha, NE 68130

EDUCATION:

1975 – 1977 M.D.
University of Nebraska Medical Center, Omaha, NE

1971 – 1975 B.S. in Biology
Nebraska Wesleyan University, Lincoln, NE

RESIDENCY:

1977 – 1980 Medical Education Program, Chief Resident
Iowa Medical Education Program, Cedar Rapids, IA

CERTIFICATIONS AND LICENSURE:

1980 – Present	Board Certified Family Practice (15494)
1980 – Present	American Academy of Family Physicians
1980 – Present	Dodge County Medical Society
1980 – Present	Nebraska Medical Association
1980 – Present	American Medical Association

PROFESSIONAL EXPERIENCE:

Principal Investigator, 2019 – Present
Cognitive Clinical Trials Research, Fremont, NE

Principal Investigator, 2011 – 2019
Synexus Clinical Research US, Inc., Fremont, NE

Physician, 2006 – Present
Prairie Fields Family Medicine, LLC., Fremont, NE

Physician, 1981 – Present
Family Practice, Fremont, NE

Medical Staff member, 1981 – Present
Fremont Area Medical Center, Fremont, NE

Chief of Medical Staff, 1996 – 1997
Fremont Area Medical Center, Fremont, NE

Vice President Medical Staff, 1995
Fremont Area Medical Center, Fremont, NE

Chairman, Credential Committee, 1986
Fremont Area Medical Center, Fremont, NE

Executive Committee, Patient Review Committee and Emergency, 1986
Fremont Area Medical Center, Fremont, NE

Emergency Room Committee, 1986, 1987, 1990, 1999
Fremont Area Medical Center, Fremont, NE

PROFESSIONAL EXPERIENCE (*continued*):

Occupational Health/Company Physician, 1980 – Present
Magnus Farley, Fremont, Nebraska

Medical Director, 1984 – Present
Geo A. Hormel, Fremont, NE

Employee Health Physicians, 1981 – 2003
Fremont Area Medical Center, Fremont, NE

Student and Athlete Health Physician, 1981 – 2003
Midland University, Fremont, NE

Emergency Room Physician, 1980 – 1981
Mercy Medical Center at St. Luke's Medical Center, Cedar Rapids, IA

INVESTIGATOR EXPERIENCE:

Allergy • Arthritis • Atrial Fibrillation • Cardiovascular • Common Cold • COPD • Diabetes
Dyslipidemia • Hyperlipidemia Influenza • Migraine • Opioid-Induced Constipation
Osteoarthritis • Pain • Post-Herpetic Neuralgia • Rheumatoid Arthritis • Vaccine

INVESTIGATOR EXPERIENCE:

Arthritis

A Phase III, Randomized, Multi-Dose, Placebo-controlled, Double-blind Study to Evaluate the Long-term Efficacy and Safety of XXX in Patients with Pain due to Osteoarthritis of the Knee or Hip

A Randomized, Double-blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk of Cardiovascular Disease Comparing XXX with XXX and XXX

Cardiovascular

A XXX Cardiovascular Morbidity and Mortality (AQCLAIM) Study in Subjects with Documented Cardiovascular Disease

Chronic Obstructive Pulmonary Disease (COPD)

A Pilot Study in COPD and asthmatic patients to ascertain patient acceptability/suitability and technological feasibility of data collection by remote monitoring devices

INVESTIGATOR EXPERIENCE (*continued*):

A 24-week Treatment, Multicenter, Randomized, Double-blinded, Double-dummy, Parallel-Group, Clinical Trial Evaluating the Efficacy and Safety of XXX/XXX Dose Combination XXX Compared with Each Monotherapy (XXX and XXX) and XXX when Administered to Patients with Stable Chronic Obstructive Pulmonary Disease

Double-blind, Randomization, Placebo-controlled, Parallel-Group, Phase IV Study to Evaluate the Effect of XXX on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD

A 12-week Multicenter, Randomization, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of XXX in Stable COPD Patients

Diabetes

A Trial Comparing the Efficacy and Safety of Insulin XXX and Insulin XXX in Subjects with Type 2 Diabetes Mellitus Inadequately Treated with Basal Insulin With or Without Oral Antidiabetic Drugs

Efficacy in Controlling Glycaemia with XXX as add-on to Metformin vs. XXX as add-on to XXX after up to 104 weeks of Treatment in Subjects with Type 2 Diabetes Inadequately Controlled with XXX Monotherapy and Treated in a Primary Care Setting

A Real World, Point-of-care, Randomized, Parallel Group, Open, 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients with Type 2 Diabetes mellitus

Six-month, Randomized, Open-label, Parallel-Group Comparison of the Insulin XXX to XXX in Adult Patients with Type 2 Diabetes Mellitus also using Insulin XXX

A Trial Comparing Cardiovascular Safety and Insulin XXX versus XXX in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events

Hyperlipidemia/ Dyslipidemia

A 52-week, Phase III, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Efficacy, Safety and Tolerability of XXX in Subjects with Primary Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

Influenza

A Randomized, Double-blind, Phase II Study Comparing the Efficacy, Safety and Tolerability of Combination Antivirals (XXX, XXX, XXX) versus XXX for the Treatment of Influenza in Adults at Risk for Complications.

INVESTIGATOR EXPERIENCE (*continued*):

A Randomized Double-blind, Phase II Study Comparing the Efficacy, Safety and Tolerability of Combination Antivirals (XXX, XXX, XXX) versus XXX for the Treatment of Influenza in Adults at Risk for Complication.

A Randomization, Double-blind, Phase II Study Comparing the Efficacy, Safety and Tolerability of Combination Antivirals XXX versus XXX for the Treatment of Influenza in Adults at Risk for Complication

A Randomization, Double-blind Study Comparing XXX versus Placebo for the Treatment of Influenza in Low Risk Adults

Migraine

A Multicenter, Randomized, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of XXX in the Acute Treatment of Migraine with or without aura

A Phase III, Multicenter, Randomized, Double-blind, Placebo controlled single attack Study to Evaluate the Efficacy, Safety and Tolerability of XXX in the Acute Treatment of Migraine

A Multicenter, Randomized, Double-blind, Parallel-Group Study evaluating the Long-term Safety and tolerability, and Efficacy of Subcutaneous Administration of XXX for the Preventative Treatment of Migraine

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Comparing the Efficacy and Safety of XXX Regimens of subcutaneous administration of XXX versus Placebo for the Preventative Treatment of Episodic Migraine

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of XXX versus Placebo for the Preventative Treatment of Chronic Migraine

An Open-label, Long-term Safety Study of XXX in the Acute Treatment of Migraine

A Study of two Doses of XXX compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Vaccines

A Phase III, Randomized, Active-controlled, observer-blinded Study to Assess the Immunogenicity, Safety, and Tolerability of XXX when administered as a 2-Dose regimen and a first-in-human Study to describe the Immunogenicity, Safety and Tolerability of a XXX vaccine (XXX) in healthy subjects 10 to <26 years of age

INVESTIGATOR EXPERIENCE (*continued*):

A Duration-of-immunity Study to Assess Persistence of hSBA response for up to 48 months After Completion of Vaccination with XXX

A Phase III, observer-blind, Randomization, controlled, Multicenter Study to Evaluate the Safety of a XXX Vaccine Produced either in Mammalian Cell Culture or in Embryonated Chicken Eggs XXX, in Healthy Children and Adolescents 4 to 17 years of age

Other Indications

A Randomized, Parallel-Group, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of XXX Nasal Spray in Adult Subjects with Symptoms of Common Cold

A Multicenter Study conducted to Evaluate the performance of the XXX test in Laboratory and Point of Care Testing Sites

A Multicenter, Randomized, Double-blind, Parallel-Group, comparative Study of XXX vs. XXX for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster-Associated Pain

A Phase III, Observer-blinded, Randomization, Active-controlled XXX, Multicenter Trial of the Safety and Immunogenicity of XXX adults 18 to 70 years of age

An Optional Prospective follow-on Study to Evaluate the Continued Efficacy and Safety of XXX in Cat Allergic Subjects up to Five Years After the Administration of Treatment

Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II

A Randomization Double-blind, Placebo-controlled, Parallel-Group, Multicenter, Phase III Study to Evaluate the Long-term Safety of XXX for the Treatment of Opioid-induced Constipation in Subjects with Nonmalignant Chronic Pain receiving Opioid Therapy